February 21, 2017. Although we support the FDA’s efforts to provide a recommended maximum level of lead as in impurity in cosmetic lip products and externally applied cosmetics, we reject the FDA’s rationale for the maximum level of 10 parts per million of lead in these products.
Read More »On Health Policy
Letter to Senators Opposing Nomination of Scott Pruitt to Head the EPA
February 15, 2017. We joined 233 other organizations in signing this letter to Senators opposing the nomination of Scott Pruitt to head the EPA.
Read More »NCHR Testimony to the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria
January 25, 2017. NCHR’s Dr. Stephanie Fox-Rawlings spoke at this meeting about effective strategies to reduce antibiotic resistance.
Read More »NCHR Comments on Manufacturer Communications on Use of Off-Label Medical Products
January 6, 2017. Based on research showing the clear risks and relatively modest benefits to patients, and the even greater costs to public health when there is inadequate evidence to make informed decisions, we strongly oppose allowing companies to promote medical products for off-label uses. These views are based on evidence and have been confirmed by speaking with hundreds of patients harmed by medical products that they did not know were being used off label.
Read More »NCHR Comment on EPA’s New Chemical Review Program
January 17, 2017. As a think tank focused on public health, we strongly agree that chemicals should be carefully evaluated before they are sold, as well as afterwards. People who work around new chemicals should be informed of the risks and the appropriate protections. Thorough evaluations of new chemicals by the EPA can reduce the risks of many new chemicals, saving lives and improving the health of people who live and work in the United States.
Read More »